ChengDa Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020
Cash & Equivalents	805.74	178.46	1,364	604.43	18.49	47.02
Trading Asset Securities	177.16	957.65	-	776.89	-	-
Cash & Short-Term Investments	982.9	1,136	1,364	1,381	18.49	47.02
Cash Growth	-16.99%	-16.70%	-1.26%	7369.47%	-60.67%	-28.34%
Accounts Receivable	110.09	97.75	126.68	111.13	93.08	63.8
Other Receivables	0.88	0.17	0.19	0.01	0.49	0.01
Receivables	110.97	97.92	126.87	111.14	93.56	63.9
Inventory	154.09	135.27	130.47	156.43	104.18	57.97
Prepaid Expenses	-	-	-	-	4.02	-
Other Current Assets	47.61	45.86	21.59	30.88	5.67	4.64
Total Current Assets	1,296	1,415	1,643	1,680	225.93	173.52
Property, Plant & Equipment	846.21	872.25	646.21	518.45	402.21	304.03
Long-Term Investments	77.41	7.41	30	30	-	-
Other Intangible Assets	35.49	36.51	33.85	34.58	39.83	41.05
Long-Term Deferred Tax Assets	8.74	8.06	4.29	4.23	2.79	2.35
Long-Term Deferred Charges	41.28	44.12	43.5	12.93	6.47	7.17
Other Long-Term Assets	63.87	52.94	54.6	41.95	6	6.09
Total Assets	2,369	2,436	2,455	2,322	683.23	534.21
Accounts Payable	157.81	189.23	139.89	77.82	57.83	31.06
Accrued Expenses	4.32	11.96	9.71	10.76	6.84	4.51
Short-Term Debt	-	-	-	-	54.06	10.01
Current Portion of Long-Term Debt	-	-	-	-	15	-
Current Income Taxes Payable	5.2	0.1	5.63	0.04	4.87	8.03
Current Unearned Revenue	2.93	2.79	11.87	6.18	7.82	1.92
Other Current Liabilities	5.23	2.69	4.43	4.74	1.37	14.3
Total Current Liabilities	175.49	206.76	171.53	99.54	147.78	69.84
Long-Term Debt	58.2	80.12	-	-	-	-
Long-Term Unearned Revenue	1.92	2.51	3.43	4.47	5.52	5.46
Long-Term Deferred Tax Liabilities	0.78	1.38	1.44	1.8	-	-
Total Liabilities	236.38	290.77	176.4	105.81	153.3	75.3
Common Stock	154.71	154.71	154.71	96.7	72.52	72.52
Additional Paid-In Capital	1,694	1,694	1,693	1,751	152.57	151.82
Retained Earnings	357.16	370.68	429.09	367.12	304.15	233.72
Treasury Stock	-57.07	-57.07	-	-	-	-
Comprehensive Income & Other	-19.2	-19.2	-	-	-	-
Total Common Equity	2,130	2,143	2,277	2,214	529.24	458.06
Minority Interest	2.66	2.64	1.8	1.68	0.68	0.85
Shareholders' Equity	2,132	2,146	2,279	2,216	529.93	458.91
Total Liabilities & Equity	2,369	2,436	2,455	2,322	683.23	534.21
Total Debt	58.2	80.12	-	-	69.06	10.01
Net Cash (Debt)	924.71	1,056	1,364	1,381	-50.56	37.01
Net Cash Growth	-21.91%	-22.58%	-1.26%	-	-	-
Net Cash Per Share	6.10	6.95	8.82	9.12	-0.44	0.32
Filing Date Shares Outstanding	151.47	151.47	154.71	154.71	116.04	116.04
Total Common Shares Outstanding	151.47	151.47	154.71	154.71	116.04	116.04
Working Capital	1,120	1,208	1,471	1,580	78.15	103.68
Book Value Per Share	14.06	14.15	14.72	14.31	4.56	3.95
Tangible Book Value	2,094	2,107	2,243	2,180	489.41	417.01
Tangible Book Value Per Share	13.82	13.91	14.50	14.09	4.22	3.59
Buildings	-	325.77	256.48	227.07	184.8	129.63
Machinery	-	701.73	430.36	328.86	313.05	248.56
Construction In Progress	-	101.46	179.17	153.53	70.7	66.63

Source: S&P Global Market Intelligence. Standard template. Financial Sources.